Literature DB >> 24550430

Vascular Ehlers-Danlos syndrome: exploring the role of inflammation in arterial disease.

Dianna M Milewicz1, Amy J Reid, Alana C Cecchi.   

Abstract

Entities:  

Keywords:  C-reactive protein; Editorials; Ehlers-Danlos syndrome, vascular type; collagen type III

Mesh：

Substances：

Year:  2014        PMID： 24550430      PMCID： PMC4331049          DOI： 10.1161/CIRCGENETICS.114.000507

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN： 1942-3268


× No keyword cloud information.
  27 in total

1.  The haploinsufficient Col3a1 mouse as a model for vascular Ehlers-Danlos syndrome.

Authors:  T K Cooper; Q Zhong; M Krawczyk; H-J Tae; G A Müller; R Schubert; L A Myers; H C Dietz; M I Talan; W Briest
Journal:  Vet Pathol       Date:  2010-06-29       Impact factor: 2.221

2.  Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK).

Authors:  P Beighton; A De Paepe; B Steinmann; P Tsipouras; R J Wenstrup
Journal:  Am J Med Genet       Date:  1998-04-28

3.  The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience.

Authors:  Gustavo S Oderich; Jean M Panneton; Thomas C Bower; Noralane M Lindor; Kenneth J Cherry; Audra A Noel; Manju Kalra; Timothy Sullivan; Peter Gloviczki
Journal:  J Vasc Surg       Date:  2005-07       Impact factor: 4.268

Review 4.  The role of neovascularisation in the resolution of venous thrombus.

Authors:  Bijan Modarai; Kevin Guiver Burnand; Julia Humphries; Matthew Waltham; Alberto Smith
Journal:  Thromb Haemost       Date:  2005-05       Impact factor: 5.249

5.  Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development.

Authors:  X Liu; H Wu; M Byrne; S Krane; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

6.  Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation.

Authors:  Sheritha P Lee; Kenneth I Ataga; Eugene P Orringer; David R Phillips; Leslie V Parise
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04-06       Impact factor: 8.311

7.  Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

Authors:  Kim-Thanh Ong; Jérôme Perdu; Julie De Backer; Erwan Bozec; Patrick Collignon; Joseph Emmerich; Anne-Laure Fauret; Jean-Noël Fiessinger; Dominique P Germain; Gabriella Georgesco; Jean-Sebastien Hulot; Anne De Paepe; Henri Plauchu; Xavier Jeunemaitre; Stéphane Laurent; Pierre Boutouyrie
Journal:  Lancet       Date:  2010-09-07       Impact factor: 79.321

Review 8.  Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction.

Authors:  René R S Packard; Peter Libby
Journal:  Clin Chem       Date:  2008-01       Impact factor: 8.327

Review 9.  Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link.

Authors:  L Lavie; P Lavie
Journal:  Eur Respir J       Date:  2009-06       Impact factor: 16.671

10.  Thrombus organization and healing in the swine experimental aneurysm model. Part I. A histological and molecular analysis.

Authors:  Daniel Lee; Ichiro Yuki; Yuicm Murayama; Alexander Chiang; Ichiro Nishimura; Harry V Vinters; Chiachien J Wang; Yih-Lin Nien; Akira Ishil; Benjamin M Wu; Fernando Viñuela
Journal:  J Neurosurg       Date:  2007-07       Impact factor: 5.115
View more
  1 in total

1.  Increased augmentation index in patients with Ehlers-Danlos syndrome.

Authors:  Maurice Roeder; Sira Thiel; Frederic Baumann; Noriane A Sievi; Marianne Rohrbach; Malcolm Kohler; Thomas Gaisl
Journal:  BMC Cardiovasc Disord       Date:  2020-09-15       Impact factor: 2.298
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.